Cambridge, UK 1/21/15; 1/23/15—Life science research–tool provider Abcam has acquired Firefly Bioworks for $28 million in cash. Firefly’s multiplex assay platform detects biomarkers. Its first product is designed to detect miRNAs. “The acquisition of Firefly represents a compelling strategic fit for Abcam, expanding our Kits and Assays business into the new areas where life science researchers tell us they have the greatest needs,” commented Abcam CEO Alan Hirzel. “RNA is one of the hottest areas in science for our consumers and we are excited about the scientific and commercial potential in what is a new product area for Abcam.” Abcam stated that the acquisition adds multiplex assay capability to its business and that it could potentially combine its RabMAb technology with this assay capability for multiplex protein measurements. Based in Cambridge, Massachusetts, Firefly has 15 employees.